

Weill Cornell Medical College Curriculum vitae and Bibliography

A. GENERAL INFORMATION

1. Name: Douglas S. Scherr
2. Office address, telephone, fax:
- Starr 900, Department of Urology
The New York Presbyterian Hospital-
Weill Medical College of Cornell University
525 East 68th Street
New York, NY 10065
- Phone: (212) 746-5788
Fax: (212) 746-0975
3. Email: dss2001@med.cornell.edu

B. EDUCATIONAL BACKGROUND

1. Degrees

Degree	Institution	Dates attended	Year awarded
B.A.	Cornell University, Arts & Sciences Ithaca, New York	8/85-5/89	1989
M.D.	The George Washington University Medical School Washington, D.C.	7/90-6/94	1994

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

Post-doctoral training:

1994-5 Intern, General Surgery
The George Washington University Hospital

1995-6 Junior Assistant Resident, General Surgery
The George Washington University Hospital
Resident in Urology
The James Buchanan Brady
Department of Urology
The New York Hospital-Cornell Medical Center
New York, N.Y.

1999-00 Chief Resident in Urology
The James Buchanan Brady
Department of Urology
The New York Hospital-Cornell Medical Center
New York, N.Y.

2000-02 Fellow, Urologic Oncology
Department of Urology
Memorial Sloan Kettering Cancer Center
New York, New York

Academic positions:

7/01-6/02 Instructor in Urology
Department of Urology
Weill Medical College of Cornell University
New York, N.Y.

7/02-6/08 Assistant Professor of Urology
Clinical Director, Urologic Oncology
Department of Urology
Weill Medical College of Cornell University
New York, N.Y.

7/08-Present Associate Professor of Urology
Clinical Director, Urologic Oncology
Weill Medical College of Cornell University
New York, N.Y.

1/03-present Visiting Associate Physician
Rockefeller University Hospital
Rockefeller University, New York, N.Y.

Hospital positions:

07/02-06/08 Assistant Attending Urologist

New York-Presbyterian Hospital
New York, N.Y.

07/08-present Associate Attending Urologist
New York-Presbyterian Hospital
New York, N.Y.

Other employment:

N/A

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure

- a. New York Date of issue 6/96
- b. Date of last registration 12/09 - 12/11

2. Board Certification

American Board of Urology 13173 2/28/03

Re-certified 2010

E. PROFESSIONAL MEMBERSHIPS

Member/officer	Name of Organization	Dates held
Diplomat	American Board of Urology	2004-Present
Member	Society of Urologic Oncology	2006-Present
Founding	Member, Executive Committee, Young Urologic Oncology Society	2006-Present
Member,	Society for Basic Urological Research	2002-Present
Member	American Urological Association	2000-Present

Member	New York Section of AUA, Co-Chair of Valentine Essay Meeting	2008-Present
Member	Society of University Urologists	1998-2004
Member	American Medical Association	1994-Present
Lecturer	American Austrian Foundation	2000-2004
Member	Cancer and Leukemia Group B (CALGB), GU Core	2002-2006

F. **HONORS AND AWARDS**

1. Name of award Date awarded

William Beaumont Medical Research Honor Society First Prize for Best Original Medical Essay, The William Shafirt Award, The George Washington University School of Medicine. "A crisis of unknown proportion: An empirical analysis of the American medical malpractice system." 1994

First Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, "BCL-2 and P53 expression in clinically localized prostate cancer as predictive markers for the response to external beam radiotherapy." 1998

First Prize for Clinical Investigation, Society of University Urology Residents, Annual Chief Resident Meeting, Marietta, Georgia. "Anti-androgen therapy for prostate cancer and the prevention of osteoporosis: The role of DES." 2000

Second Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, "Collagen Type I Crosslinked N-Telopeptide as a urinary marker for osteoporosis in prostate cancer: The role of Diethylstilbesterol (DES)." 2000

Pfizer, Scholars in Urology Award, Awarded for advancing the scientific and clinical field of urology. 2000

Ferdinand C. Valentine Fellowship for Research in Urology. The New York Academy of Medicine. 2001-2002. Syndecan-1 expression in prostate cancer and the role of p27 in primary prostate epithelial cell transformation.

T32 Research Training Grant. Memorial Sloan Kettering Cancer Center. 2000-2002.

Edwin Beer Research Award. NY Academy of Medicine. Effective Tumor Immunotherapy in Transitional Cell Carcinoma of the Bladder. 2005-2007

Career Development Award. Kidney Urology Foundation of America. The role of the Pim-1 Oncoprotein in Prostate Carcinogenesis. 2004-2005

Best Video Award. Society of Laparoscopic Surgery. Oncological Outcomes of Robotic Cystectomy. San Francisco, CA August, 2007.

G. INSTITUTIONAL/HOSPITAL AFFILIATION

1. Primary Hospital Affiliation NYPH
2. Other Hospital Affiliations: Rockefeller University Hospital

H. EMPLOYMENT STATUS

1. Name of Current Employer: Weill Cornell Medical College

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT

1. Teaching:

Lecture to 1st year medical students on pelvic anatomy. Teach course to surgical residents on retroperitoneal and pelvic anatomy. Fall semester on a yearly basis since 2004

Lecture to 3rd year medical students on urologic oncology 4x/year. Give Grand Rounds in Urology and General Surgery several times a year. Recurring since 2002

2. Clinical care :

Clinical Director , Urologic Oncology, since 7/02. Treat patients with urologic oncology diseases every week. Perform 8 -10 major surgical cases per week.

3. Administrative duties:

a. Weill Medical College Admissions Committee Member since 2007

b. Hospital Committee on DVT Prophylaxis 2007

4. Research:

Since 2002 I have maintained an active basic science and clinical research effort. My main focus in the laboratory setting has been in the area of bladder cancer therapeutics and tumor immunology. To be specific, I have worked on developing novel therapies for the intravesical treatment of superficial bladder cancer. My work has focused on a group

of compounds called imidazoquinolines. These are Toll Like Receptor antagonists that cause dendritic cell activation with subsequent CD8 lymphocyte activation against bladder tumor antigen. We are about to start a phase I trial in human patients as a result of my pre-clinical work. Further, I am now collaborating with the lab of Dr. Laurie Glimcher to evaluate the role of the ER stress response in bladder cancer. We are working to test an inhibitor of the IRE1/XBP1 pathway for the intravesical treatment of bladder cancer.

From a clinical standpoint since 2008, I have focused a great deal of effort in my work developing an multiphoton endoscope. To this end, I have collaborated quite closely with my counterparts at Cornell-Ithaca. In particular, I have worked most closely with Professor Watt W. Webb and Professor Chris Xu in the Department of Applied Engineering and Physics. We now have a prototype available for which we are in the midst of animal testing and hope to move toward human use in the next few years. In addition, I maintain large, robust clinical databases in bladder, prostate and kidney cancer. I was the first physician at NYPH-Weill Cornell to perform a robotic prostatectomy and the first to perform a robotic cystectomy. I have been a pioneer in the development of the field of robotic surgery for bladder cancer and I have the largest, single-surgeon series of robotic cystectomies.

J. RESEARCH SUPPORT

Current/Past

NY Academy of Medicine/Valentine Research Award in Urology
Role of p27 in Prostate Epithelial Cell Differentiation
PI: Douglas S. Scherr, M.D.
Total award: \$50,000
Dates: 2001-2003

Kidney Urology Foundation of America
Career Development Award
The Role of PIM-1 Oncogene in Prostate Carcinogenesis
PI: Douglas S. Scherr, M.D.
Total Award: \$50,000
Dates: 2002-2004

Edwin Beer Research Award
Effective Tumor Immunotherapy in Superficial Bladder Cancer
Total Award: \$40,000/year for 2 years
Dates: 2004-2006

3M Pharmaceuticals

Phase I Trial of Imiquimod-like Compound in the Treatment of Superficial Bladder Cancer

PI: Douglas S. Scherr, M.D.

Total Award: \$112,000

Dates: 2004-2008

Empire Clinical Research Investigator Award.(ECRIP). Development of Direct Medical Applications of Multiphoton Microscopy to Solve Crucial Diagnostic Challenges in Urology: The Use of Two-Photon Tissue Imaging in the Evaluation and Diagnosis of Malignancy. \$60,000/yr for 2 years

Dates: 2002-2004

NBIB/NIH Bioengineering Partnership Grant. Multiphoton Endoscopy Development. Co-investigator. \$2,000,000 Award. PI: Professor Watt W. Webb, PhD

Weill Medical College-Cornell University Seed Grant. PI. The development of multiphoton endoscopy in bladder cancer. \$50,000.

Dates: 2008

Weill Medical College-Cornell University Seed Grant. PI. Microfluidic Chip Development in the diagnosis of Urothelial Cell Carcinoma. \$50,000.

Dates: 2006

National Institutes of Health Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center PI: Douglas Scherr Performance Period: 2013 – 2014.

PI: Douglas Scherr, M.D.

5% effort. Total \$35,000

National Center for Advancing Translational Sciences|
Metabolomic Profiling of Non-Muscle Invasive Bladder Cancer

PI: Douglas Scherr

\$50,000 per year

Performance Period: May 2013 – May 2014

Project Title: Development of Novel Diagnostic Imaging Applications for Prostate Cancer

Grant/Protocol Number: Ferdinand C Valentine Fellowship

Sponsor: New York Academy of Medicine

PI: Douglas Scherr, M.D.

Received: 2014-06-17

Amount: \$50,000

Term: 1 year

Pending:

Project Title: Nanoparticles: Imaging and Focal Hyperthermia in Prostate Cancer
Grant/Protocol Number: 2015 AUA Urology Care Foundation Research Scholar
Sponsor: American Urology Association/Urology Care Foundation
PI: Douglas Scherr, M.D.
Deadline: 2014-08-24
Amount: \$40,000-50,000
Term: 1 year

Past Clinical Trials:

Effective Tumor Immunotherapy in Bladder Cancer. Principal Investigator, Weill Medical College of Cornell University IRB # 0103-647, Approved 12/02, Renewed Approval 11/03. This protocol employs leukopheresis pre and post-BCG therapy in patients with superficial bladder cancer in an attempt to identify a specific CD-8 lymphocyte response to tumor antigen that is initiated by BCG. A total of 9 patients have enrolled and completed the trial.

A Randomized, Placebo Controlled Phase II Study of Celecoxib in Patients with Recurrent Superficial Bladder Cancer, Co-PI at Cornell Site, Main PI: Dr. Guido Dalbagni, Memorial Sloan Kettering Cancer Center. Goal is to assess the role of Celecoxib in the prevention of superficial bladder cancer. Weill Medical College of Cornell University IRB # 0903-894.

Role of Renal Biopsy in the Preoperative Determination of Histology in Patients with Renal Cell Carcinoma. Principal Investigator, Weill Medical College of Cornell University. Intraoperative renal biopsies performed prior to radical or partial nephrectomy with subsequent FISH analysis for pathological interpretation. IRB #: 0802-408.

Current Active Protocols

Protocol #	Protocol Name
1311014490	An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists. PI: Scherr, DS
1311014489	89Zr-Df-IAB2M Imaging of Localized Prostate Cancer. PI: Scherr, DS
1302013537	A Clinical, non-intervention study of the Cxbladder® urine test for the detection of recurrent urinary tract Urothelial Carcinoma (UC) PI: Scherr, DS

1301013497 Evaluation of the Xpert® Bladder Assay For Monitoring of Recurrence in Bladder Cancer Patients and Detection of Bladder Cancer in Symptomatic Patients. **PI: Scherr, DS**

1202012209 89Zr-J591 Imaging of Localized Prostate Cancer . **PI: Scherr, DS**

1109011951 The Impact of Early Feeding after Radical Cystectomy for Bladder Cancer Co-PI: **Scherr, DS**

1106011737 Prostate Cancer Tissue Bank and Database. **PI: Scherr, DS**

1011011386 Molecular Profiling of Bladder Cancer. **PI: Scherr, DS**

1007011131 Discovery of Biomarkers for Bladder and Kidney Cancer. **PI: Scherr, DS**

0711009545 Development of the Cornell Prostate Cancer Biobank for the National Cancer Institute-Early Detection Research Network (NCI-EDRN) for Prostate Cancer Biomarker Research. **PI: Scherr, DS**

0506007919 Use of Multiphoton Microscopy in the Diagnosis of Disease. **PI: Scherr, DS**

1205012389 A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology. **PI: Scherr, DS**

0807009900 Renal Tumor Database. **PI: Scherr, DS**

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

2002-present Journal of Urology

2002-present Journal of the National Cancer Institute

2002-present American Journal of Pathology

2002-present Urology

2004-present The Prostate

2002-present International Journal of Cancer

2006-present Journal of Clinical Oncology

2004-present Journal of Urological Oncology

2005-present Oncology
2006-present European Urology
2004-present Journal of British Urology

Consulting

2008-2012 Boston Scientific Cooperation
2008-2011 Endopharmaceuticals/AMS

VISITING FELLOW/PROFESSORSHIPS:

2/98 Visiting fellowship, February, 1998; Salzburg General Hospital, Salzburg, Austria

12/02 Visiting Professorship, December 6-13, 2002, Salzburg Seminar, Salzburg, Austria

8/07 Visiting Professorship. Salzburg Seminars. Surgical Management of bladder Cancer.

5/11 Visiting Professorship. Bellinson Hospital, Department of Urology, Tel Aviv, Israel

INVITED LECTURES:

10/02 The Changing Face of Hormonal Therapy in the Treatment of Prostate Cancer, Urology Grand Rounds, Brookdale Hospital, New York

9/03 A Modern Approach in the Treatment of Testicular Germ Cell Tumors. General Surgery Grand Rounds, Weill Medical College of Cornell University. Septmeber, 2003

11/05 2005 Mini-Board Review for Residents. Management of Superficial Bladder Cancer. NY Academy of Medicine.

11/06 Course Director, Current Trends in GU Malignacies. New York Marriot.

20012-Present: American Urology Association Sanctioned Course on “Management of Upper Urinary Tract Urothelial Cell Carcinoma”. Faculty Member

BROADCAST INTERVIEWS:

9/03 WNBC-TV New York: “Treatment Options for Prostate Cancer”

9/03 NY-1-TV New York: “Radiation and Surgical Treatments of Prostate Cancer”

2/04 WNBC-TV New York, “Screening for prostate cancer in African American Men”

L. BIBLIOGRAPHY

ARTICLES IN PROFESSIONAL PEER-REVIEWED PUBLICATIONS:

1. Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, Fair WR, **Scherr DS**, Bosl GJ, Scher HI. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with five year follow-up. *J Clin Oncol* 12:1394-1401, 1994
2. **Scherr DS**, Poppas DP. Laser tissue welding. In, *Technologic Advances in Urology: Implications for the Twenty-first Century*. *Urol Clin N Amer* 25: 123-35, 1998.
3. Poppas DP, **Scherr, DS**. Laser tissue welding: a urological surgeon’s perspective. *Haemophilia* 4:456-462, 1998.
4. **Scherr, DS**, Poppas DP. Laser welding in urology. *AUA Update Series XVII*: pp1-6, 1998.
5. **Scherr, DS**, Chen A, Eid JF. A case report: In vivo excision of an angiomyolipoma from a living related renal transplant. *J Urol*, 163: 1859, 2000.
6. **Scherr, DS**, Vaughan ED Jr, Wei JT, Chung M, Felson D, Allbright R, Knudsen BS: Bc1-2 and P53 Expression in clinically localized prostate cancer predicts the response of patients to external beam radiotherapy. *J Urol* 162: 12-16, 1999.
7. **Scherr, DS**, Goldstein M. Comparison of bilateral versus unilateral varicocelectomy in men with palpable bilateral varicoceles. *J Urol* 162: 85-88, 1999.
8. **Scherr, DS**, Eastham, J, Ohori M, Scardino PT. Prostate biopsy techniques and

indications: when, where and how? *Semin Urol Oncol* 20(1):18-31, 2002.

9. **Scherr, DS**, Pitts WR, Vaughan ED. DES Revisited: Anti-androgen therapy, osteoporosis and prostate cancer. *J Urol*, 167: 535-538, 2002.
10. **Scherr DS**, Swindle and Scardino, PT. NCCN Guidelines for the Management of Prostate Cancer. *Urology* 61 (Suppl 2A): 14-24, 2003.
11. **Scherr, DS** and Pitts, WR. Androgen Deprivation Therapy Without Estrogen Deprivation: The Non-Steroidal Effects of Estrogens in the Treatment of Prostate Cancer. *J Urol* 170(5): 1703-08, 2003
12. Knudsen, BS, Gmyrek, GA, Inra, J, **Scherr, DS**, Vaughan, ED, Nanus, DM, Kattan, MW, Gerald, WL and Vande Woude, G. High Expression of the Met receptor in prostate cancer metastasis to bone. *Urology*, 60(60): 1113-1117, 2002.
13. **Scherr, DS**, NG C, Munver, R, Sosa, RE, Vaughan, ED, et al. Practice Patterns Among Urologic Surgeons Treating Localized Renal Cell Carcinoma in the Laparoscopic Age: Technology vs. Oncology. *Urology*, 62(6): 1007-12, 2003.
14. Richstone L, **Scherr, DS**, Reuter, VE, Snyder ME, Rabbani F, Kattan M and Russo P. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. *J Urol*, 171(2 pt 1): 615-20, 2004
15. Chen, DY, Sosa, RE and **Scherr, DS**. Treatment of Adrenocortical Carcinoma: Contemporary Outcomes. *Current Urology Reports*, 5(1): 65-72, 2004
16. Boorjian S, Tickoo S, Mongan N, Nanus D, Yu H, Bok D, Rando R, **Scherr DS**, and Gudas L. Loss of Lecithin:Retinol Acyltransferase (LRAT) Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer. *Cancer Res*, 10: 3429-3437, May 15, 2004.
17. Boorjian S, Ugras S, Mongan N, Gudas L, Tickoo S and **Scherr DS**. Androgen Receptor Expression is Inversely Correlated with Pathologic Tumor Stage in Transitional Cell Carcinoma of the Bladder. *Urology* 64(2): 383-88, 2004.
18. Boorjian S, Ng C, Sosa RE, Munver R, Delpizzo J, Vaughan ED and **Scherr DS**. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. *Urology*, 66(2): 283-7, Aug 2005.
19. Boorjian S, Ng C, Munver R, Palese MA, Sosa RE, Vaughan EDV, Delpizzo JJ and **Scherr DS**. Abnormal Selective cytology results predict recurrence of upper-tract transitional cell carcinoma treated with ureteroscopic laser ablation. *J Endourol*, 18(9): 912-6, Nov 2004.

20. Boorjian, S., **Scherr, D.S.**, Mongan, N.P., Zhuang, Y., Nanus, D.M., and Gudas, L.J. Retinoid Receptor mRNA Expression Profiles in Human Bladder Cancer Specimens. *Int J Oncol*, 26(4): 1041-48, Apr. 2005.
21. Barocas DA, Kawamoto H, Dreizin DF, Howard ME, Choi J, Pitts WR, You X, Tickoo SK, Boorjian SA, **Scherr DS**: Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome. *Urology* 66(5): 1134-39, 2005.
22. Shelton JB, Barocas DA, Conway F, Hart K, Nelson K, Richstone L, Gonzalez RR, Raman JD and **Scherr DS**. Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large scale population based studies. *Urology*, 65(5): 931-6, 2005.
23. Raman, JD, Mongan, NP, Tickoo, SK, Boorjian, SA, **Scherr, DS** and Gudas, LJ. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. *Clin Can Res*, 11(24): 8570-76, Dec. 2005.
24. Raman JD, Ng CK, Boorgian SA, Vaughan EDV, Sosa RE and **Scherr DS**. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. *BJU Int*, 96(7): 1031-5, Nov. 2005.
25. Barocas, DA, Rabbani, F, **Scherr, DS** and Vaughan, EDV. A population based study of renal cell carcinoma and prostate cancer in the same patients. *BJU Int.*, 97(1): 33-6, 2006
26. Raman JD, Palese MA, Ng CK, Boorjian SA, **Scherr DS**, Delpizzo JJ and Sosa RE. Hand-assisted laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. *JSLS*, 10(4): 432-8, 2006.
27. Barocas, DA, Rohan, SM, Kao, J, Gurevich, RD, Delpizzo, JJ, Vaughan, ED, Akhtar, M, Chen, YT and **Scherr, DS**. Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis. *J Urol*, 176(5): 1957-62, 2006.
28. Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, **Scherr DS** and Gudas LJ. Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma. *Carcinogenesis*, 27(3): 499-507, 2006.
29. Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu, H and **Scherr DS**. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. *J Urol*. 177(6): 2347-51, 2007.
30. Raman JD, Sosa RE, Vaughan ED and **Scherr DS**. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. *Urology*, 69(2): 251-4, 2007

31. Herman MP, Raman JD, Dong S, Levinson A, Samadi D and **Scherr DS**. Robotic radical prostatectomy: operative technique, outcomes and learning curve. *JLS*, 11(4): 438-42, 2007.
32. Barocas DA, Mathew S, Delpizzo JJ, Vaughan ED, Sosa RE, Fine RG, Akhtar M and **Scherr DS**. Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle biopsy specimen. *BJU Int*, 99(2): 290-95, 2007.
33. Raman JD and **Scherr DS**. Management of patients with upper urinary tract transitional cell carcinoma. *Nat Clin Pract Urol*, 4(8): 432-43, 2007
34. Wang GJ, Barocas DA, Raman JD and **Scherr DS**. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. *BJU Int*. 101(1): 89-93, Sept. 2007.
35. Liu H, Schwartz MJ, Hwang D and **Scherr DS**. Tumor Growth inhibition by an imidazoquinoline is associated with c-myc down regulation in urothelial cell carcinoma. *BJU Int*. 101(7): 894-901, 2007.
36. Schwartz MJ, Hwang D, Hung A, Han J, Vaughan ED and **Scherr DS**. The negative influence of changing biopsy practice patterns on the predictive value of prostate specific antigen for cancer detection on prostate biopsy. *Cancer*, 112(8): 1718-25, 2007.
37. Richstone L, Bianco FJ, Shah H, Kattan MW, Eastham JA, Scardino PT and **Scherr DS**. Radical prostatectomy in men seventy years or older: impact of age on upgrading, upstaging and preoperative nomogram accuracy. *BJU Int*. 101(5): 541-6, 2007.
38. Seandel M, James D, Shmelkov SV, Falciatori I, Kim J, Chavala S, **Scherr DS**, Zhang F, Rorres R, Gale NW, Yancopoulos GD, Murphy A, Valenzuela DM, Hobbs RM, Pandolfi PP and Rafii S. Generation of functional multipotent adult stem cells from GPR 125+ germline progenitors. *Nature*. 449(7160): 346-50, Sept. 2007.
39. Jhaveri JK, Tan GY, **Scherr DS** and Tewari AK. Robotic-assisted laparoscopic radical prostatectomy in the renal allograft transplant recipient. *J Endourol*, 22(11): 2475-9, 2008
40. Raman JD, Shariat SF, Karakiewicz PI, Lotan Y, Sagalowsky A, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, **Scherr DS**, Remzi M, et al., Does preoperative symptom classification impact prognosis in patients with clinically localized upper tract urothelial cell carcinoma managed by radical nephroureterectomy. *Urol Oncol*. 2011 Nov-Dec;29(6):716-23
41. Ng CK, Shariat SF, Lucas SM Bagrodia A. Lotan Y, **Scherr DS**, Raman JD. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper tract urothelial carcinoma? *Urol Oncol*. 2011 Jan-Feb;29(1):27-32. Epub 2008 Dec 30.

42. Schwartz MJ, Liu H, Hwant DH, Kawamoto H, **Scherr DS**. Antitumor effects of an imidazoquinoline in renal cell carcinoma. *Urology* 2009 May;73(5):1156-62. Epub 2009 Jan1.
43. Kauffman EC, Barocas DA, Chen YT, Yang XJ, **Scherr DS**, Tu JJ. Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes. *J Urol.* 2009 May;181(5)2305-11. Epub 2009 Mar 19.
44. Mukherjee S, Wysock JS, NG CK, Akhtar M, Perner S, Lee MM, Rubin MA, Maxfield FR, Webb WW, **Scherr DS**. Human bladder cancer diagnosis using Multiphoton microscopy. *Proc Soc Photo Opt Instrum Eng.* 2009;7161:nihp96839.
45. Ng CK, Kauffman EC, Lee MM, Otto BJ, Portnoff A, Ehrlich JR, Schwartz MJ, Wang GJ, **Scherr DS**. A comparison of postoperative complications in open versus robotic cystectomy. *Eur Urol.* 2010 Feb;57(2):274-81. Epub 2009 Jun 10.
46. Raman JD, Ng CK, **Scherr DS**, Margulis V, Lotan Y, Bensalah K. Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Strobel P, Fernandez M, Karakiewicz, Shariat SF. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. *Eur Urol.* 2010 Jun;57(6): 1072-9. Epub 2009 Jul 15.
47. Kauffman EC, Ng CK, Lee MM, Otto BJ, Portnoff A, Wang GJ, **Scherr DS**. Critical analysis of complications after robotic-assisted radical cystectomy with identification of preoperative and operative risk factors. *BJU Int.* 2010 Feb;105(4):520-7 Epub 2009 Sep 4.
48. Ehrlich JR, Schwartz MJ, Ng CK, Kauffman EC, **Scherr DS**. The impact of multiple malignancies on patients with bladder carcinoma: a population-based study using the SEER database. *Adv Urol.* 2009;406965. Epub 2009 Dec 28.
49. Barberi CE, Schwartz MJ, Boorjian SA, Lee MM, **Scherr DS**. Ureteroileal anastomosis with intraluminal visualization: technique and outcomes. *Urology.* 2010 Dec;76(6): 1496-500. Epub 2010 Apr 9.
50. Brien JC, Shariat SF, Herman MP, NG CK, **Scherr DS**, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian Sa, Raman JD. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. *J Urol.* 2010 Jul;184(1):69-73. Epub 2010 May 15.
51. Shariat SF, Chade DC, Karakiewicz PI, **Scherr DS**, Dalbagni Gi. Update on intravesical

- agents for non-muscle invasive bladder cancer. *Immunotherapy*. 2010 May;2(3):381-92.
52. Kauffman EC, Ng CI, Lee MM, Otto BJ, Wang GJ, **Scherr DS**. Early oncological outcomes for bladder urothelial carcinoma patients with robotic-assisted radical cystectomy. *BJU Int*. 2011 Feb;107(4):628-35. Doi: 10.1111/j.1464-410X.2010.09577.x.Epub 2010 Sep 30.
 53. Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, **Scherr DS**, Shariat SF. Tissue-based molecular markers for bladder cancer. *Minerva Urol Nefrol*. 2010 Sep;62(3):241-58.
 54. Skukla PJ, **Scherr DS**, Milsom JW. Robot-assisted surgery and health care costs. *N Engl J Med*. 2010 Nov 25;363(22):2174; author reply 2176. No abstract available.
 55. Cha Ek, Wiklund NP, **Scherr DS**. Recent advances in robot-assisted radical cystectomy. *Curr Opin Urol*. 2011 Jan;21(1):65-70
 56. Shariat SF, Savage C, Chromecki TF, Sun M, **Scherr DS**, Lee Rk, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, Vickers AJ. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. *Cancer*, 117(13): 2892-7, 2011
 57. Messer J, Shariat SF, Brien JJC, Herman MP, NG Ck, **Scherr DS**, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. *BJU Int.*, 108(5):701-5, 2011
 58. Sonpavde G. Khan MM, Svatek Rs, Lee R, Novara G. Tiki D. Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W. Fritsch HM, Izawa JI, **Scherr DS**, Ficarra V, Dinney CP, Lotan Y, Fradet Y, Shariat SF. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. *J. Urol*. 2011 Apr; 185(4):1216-21. Epub 2011 Feb22.
 59. Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, **Scherr DS**, Gudas LJ, Mongan NP. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. *Mol Carcinog*. 2011 Dec;50(12):931-44.
 60. Chromecki TF, Ehdaie B, Novara G, Pummer K, Zipeuner R, Seitz C, Pycha A, Lee RK, Cha EK, Karakiewicz PI, NG C, Raman JD, Chun FK, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Bastian PJ, Martinez-Salamanca JI, **Scherr DS**, Shariat SF. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. *World J Urol*. 2011 Aug;29(4):473-80.
 61. Lee R, Ng CK, Shariat SF, Borkina A, Guimento R, Brumit KF, **Scherr DS**. The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy.

BJU Int. 2011 Dec;108(11):1886-92.

62. Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, Novara G, Raman JD, NG C, Lowrance WT, **Scherr DS**, Shariat SF. Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. *J Urol*. 2011 Jul;186(1):66-72. Epub 2011 May 14.
63. Cha EK, Ng CK, Jeun B, Dunning A, Reifsnnyder JE, Dipietro JR, Mazumdar M, Shih G, Auh YH, Del Pizzo JJ, Shariat SF, **Scherr DS**. Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy. *World J Urol*. 2011 May 21.
64. Verhoest G, Shariat SF, Chromecki TF, Raman JD, Margulis V, Novara G, Seitz C, Remzi M, Roupret M, **Scherr DS**, Bensalah K. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. *World J. Urol*. 2011 Aug;29(4):495-501. Epub 2011 Jun 17.
65. Shariat SF, Savage C, Chromecki TF, Sun M, **Scherr DS**, Lee RK, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, Vickers AJ. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. *Cancer*. 2011 Jul 1;117(13):2892-7.
66. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, **Scherr, DS**, Novara G, Karakiewicz PL, Shariat SF; Medscape. Prognostic factors for upper urinary tract urothelial carcinoma. *Nat Rev Urol*. 8(8):440-7, 2011
67. Mutsushita, K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H, Sun M, Karakiewicz PI, **Scherr DS**, Shariat SF. Immunohistochemical biomarkers for bladder cancer prognosis. *Int J Urol*. 2011 Sep;18(9):616-29. Doi: 10.1111/j.1442-2042.2011.02809x. Epub 2011 Jul 20.
68. Barbieri CE, Cha EK, Chromecki TF, Dunning A, Lotan Y, Svatek RS, **Scherr DS**, Karakiewicz PI, Sun M, Mazumdar M, Shariat SF. Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. *BJU int*. 2012 Mar;109(5):685-90. Doi: 10.1111/j. 1464-410X.2011.010419.x. Epub 2011 Aug 18.
69. Lee R, Chughtai B, Herman M, Shariat SF, **Scherr DS**. Cost-analysis comparison of robot-assisted laparoscopic radical cystectomy (RC) vs open RC. *BJU Int*. 108(6 Pt 2):976-83, 2011.
70. Shariat SF, Chromecki TF, Hoefler J, Barbieri CE, **Scherr DS**, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT. Soluble gp 130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. *J Urol*. 2011 Nov; 186(5):2107-14. Epub 2011 Sep 23.

71. Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, **Scherr DS**, Lotan Y, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, Shariat SF. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. *Eur urol.* 2012 Feb;61(2):245-53. Epub 2011 Sep 28.
72. Rink M, Chun FK, Robinson B, Sun M, Karakiewicz PI, Bensalah K, Fisch M, **Scherr DS**, Lee Rk, Margulis V, Shariat SF. Tissue-based molecular markers for renal cell carcinoma. *Minerva Urol Nefrol.* 2011 Dec;63(4):293-308.
73. Brookman-May S, May M, Zigeuner R, Shariat SF, **Scherr DS**, Chromecki T, Moch H, Wild PJ, Mohamad-Al-Ali B, Cindolo L, Wiseland WF, Schips L, De Cobelli O, Rocco B, Santoro L, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Hohenfellner M, Gilfrich C, Wirth MP, Burger M, Pathernik S; CORONA Project (Collaborative Research on Renal Neoplasms Association). Collecting system invasion and Fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma. *J Urol.* 2011 Dec;186(6):2175-81. Epub 2011 Oct 19.
74. Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, **Scherr DS**, Gonen M. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. *Eur Urol.* 2012 Feb;61(2):237-42. Epub 2011 Oct 21.
75. Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, **Scherr DS**, Tagawa ST, Shariat SF. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). *BJU Int.* 109(7): 968-85, 2012
76. Shariat SF, **Scherr DS**, Gupta A, Bianco FJ Jr, Karakiewicz PI, Zeltser IS, Samadi DB, Akhavan A. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. *Arch Esp Urol.* 2011 Oct;64(8):681-94.
77. Chromecki TF, Cha EK, Pummer K, **Scherr DS**, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Prognostic value of insulin-like factor II mRNA binding protein 3 in patients treated with radical prostatectomy. *BJU Int.* 110(1): 63-8, 2012
78. Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, **Scherr DS**, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y. Risk stratification of organ bladder cancer after radical cystectomy using cell cycle related biomarkers. *J Urol.* 2012 Feb;187(2):457-62. Epub 2011 Dec 15.
79. Clements T, Messer JC, Terrell JD, Herman MP, Ng CK, **Scherr DS**, Scoll B, Boorjian SA, Uzzo RG, Willie M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD. High-grade ureteroscopy biopsy is associated with advanced pathology of upper-tract

- urothelial carcinoma tumors at definitive surgical resection. *J Endourol.* 2012 Apr;26(4):398-402. Epub 2012 Feb 24.
80. Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, Lotan Y, Raman JD, Kassouf W, Seltz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz Pl, **Scherr DS**, Shariat SF. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *J Urol.* 2012 Mar; 187(3):845-51. Epub 2012 Jan 15.
 81. Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, **Scherr DS**, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Endale B, Tritschler S, Fajkovic H, Martinez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz Pl, Margulis V. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur Urol.* 2012 Apr;61(4):818-25. Epub 2012 Jan 23.
 82. Shariat SF, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman JD, Remzi M, Koppie TM, Bensalah K, Guo CC, Mikami S, Sircar K, Ng CK, Haitel A, Kabbani W, Chun FK, Wood CG, **Scherr DS**, Karakiewicz Pl, Langner, C. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. *Eur Urol.* 62(2):224-31, 2012
 83. Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo Da Pozzo L, Bertini R, Ficarra V, Otto W, Karakiewicz Pl, Pycha A, Fajkovic H, Naspro R, **Scherr DS**, Montorsi F, Shariat SF, International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. *BJU Int.* 110(5):674-81, 2012
 84. Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz Pl, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, **Scherr DS**, Shariat SF; for the Bladder Cancer Research Consortium (BCRC). Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. *Eur Urol.* 62(4):677-84, 2012
 85. Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, Sagalowsky AI, Chun FK, Karakiewicz Pl, Fisch M, **Scherr DS**, Shariat SF. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. *Curr Urol Rep.* 2012 Apr;13(2):122-35.
 86. Kauffman EC, Liu H, Schwartz MJ, **Scherr DS**. Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model. *J Oncol.* 2012, Published online Feb 22, 2012

87. Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N, Stenzel B, Schaefer G, Horninger W, Bektic J, Chinnalyan AM, Goldenberg S, Siddiqui J, Regan MM, Kearney M, Soong TD, Rickman DS, Elemento O, Wei JT, **Scherr DS**, Sanda MA, Bartsch G, Lee C, Klocker H, Rubin MA. Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated prostate cancer risk. *Proc Natl Acad Sci USA* 2012 Apr 24;109(17):6686-91. Epub 2012 Apr 10.
88. Green DA, Durand M, Gumperi N, Rink M, Cha EK, Karakiewicz PI, **Scherr DS**, Shariat SF. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. *BJU Int.*110(10): 1463-70, 2012
89. Jain M, Robinson BD, **Scherr DS**, Sterling J, Lee MM, Wysock J, Rubin MA, Maxfield FR, Zipfel WR, Webb WW, Mukherjee S. Multiphoton microscopy in the evaluation of human bladder biopsies. *Arch Pathol Lab Med.* 2012 May;136(5):517-26.
90. Wynter C, **Scherr DS**, Herman MP. A 38-year-old woman with multiple renal masses and a history of ovarian cancer. *Case Report. Urology.* 79(6):1210-3, 2012
91. Sooriakumaran P, John M, Christos P, Bektic J, Bartsch G, Leung R, Herman M, **Scherr DS**, Tewari A. Models to predict positive biopsies using the Tyrol screening study. *Urology.* 2011 Oct;78(4):924-9. Epub 2011 Aug 16.
92. Rink m, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, NG CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, **Scherr, DS** Shariat SF. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. *J Urol.* 188(2):398-404, 2012
93. Najari BB, Ramasamy R, Sterling J, Aggarwal A, Sheth S, Li PS, Dubin JM, Goldenberg S, Jain M, Robinson BD, Shevchuk M, **Scherr, DS**, Goldstein M, Mukherjee S, Schlegel PN. Pilot study of the correlation of multiphoton tomography of ex vivo human testis with histology. *J. Urol.*, 188(2):538-43, 2012.
94. Shariat SF, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joui A, **Scherr, DS**, Gonen M. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. *Eur Urol.*2013 Feb;63(2):371-8.
95. Rink M, Xylinas E, MMargulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, **Scherr, DS**, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration. Impact of

- smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. *Eur Urol.* 2013 Jun;63(6):1082-90.
96. Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, **Scherr, DS**, Shariat SF. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. *BJU Int.* 2013 Mar;111(3):404-11.
 97. Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuci E, Kassouf W, Martinez-Salamanca JI, Lotan Y, Seitz C, Pycia A, Zigeuner R, Karakiewicz PI, **Scherr DS**, Vickers AJ, Shariat SF. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. *Ann Surg Oncol.* 2012 Dec;19(13):4337-44. Doi: 10.1245/s10434-012-2499-8. Epub 2012 Jul 18.
 98. Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycia A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, **Scherr DS**, Shariat SF. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. *BJU Int.* 2013 Jan; 111(1):74-84. Doi: 10.1111/j.1464-410X.2012.11356.x. Epub 2012 Jul 18.
 99. Kaplan SA, Lee RK, Chung DE, TE AE, **Scherr DS**, Tweari, A, Vaughan ED. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5 α -reductase inhibitors markedly enhances the detection rate of prostate cancer. *J Urol.* 2012 Sep; 188(3):757-61. Doi: 10.1016/j.juro.2012.04.111. Epub 2012 Jul 19.
 100. Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, **Scherr DS**, Lotan Y, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? *World J Urol.* 2012 Dec;30(6):807-14. Doi: 10.1007/s00345-012-0910-5. Epub 2012 Jul 19.
 101. Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breini E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joul A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, **Scherr DS**, Shariat SF. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. *Eur Urol.* 2013 Nov;64(5):837-45. Doi: 10.1016/j.euro.2012.07.026. Epub 2012 Jul 20.
 102. Reifsnnyder JE, Ramasamy R, Ng CK, Dipietro J, Shin B, Shariat SF, Del Pizzo JJ,

- Scherr DS.** Laparoscopic and open partial nephrectomy: complication comparison using the Clavien system. *JLS*. 2012 Jan-Mar;16(1):38-44. Doi: 10.4293/108680812X13291597716942.
103. Xylinas E, Roupret M, Kluth L, **Scherr DS**, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration. Collaborative research network as a platform for virtual multidisciplinary, international approach to managing difficult clinical cases: an example for the Upper Tract Urothelial Carcinoma Collaboration. *Eur Urol*. 2012 Nov;62(5):943-5. Doi: 10.1016/j.eururo.2012.08.022. Epub 2012 Aug 20.
104. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, **Scherr DS**, Shariat SF, Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. *Eur Urol*. 2013 Apr;63(4):724-32. Doi: 10.1016/j.eururo.2012.08.025. Epub 2012 Aug 21.
105. Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hanse J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, **Scherr DS**, Sjoberg DD, Shariat SF. Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int*. 2013 Mar;111(3 Pt B):E30-6. Doi: 10.1111/j.1464-410X.2012.11433.x. Epub 2012 Sep 3.
106. Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, **Scherr DS**, Shariat SF, Lee RK. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. *BJU Int*. 2013 Mar;111(3 Pt B):E78-84. Doi: 10.1111/j.1464-410X.2012.11454.x. Epub 2012 Sep 7.
107. Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carbalido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, **Scherr DS**, Sonpavde G, Roupret M, Shariat SF. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World J Urol*. 2013 Feb;31(1):5-11. Doi: 10.1007/s00345-012-0939-5. Epub 2012 Sep 26.
108. Green DA, Rink M, Xylinas E, Matin SF, Stenzi A, Roupret M, Karakiewicz PI, **Scherr DS**, Shariat SF. Urothelial carcinoma of the bladder and upper tract: disparate twins. *J Urol*. 2013 Apr;189(4):1214-21. Doi: 10.1016/j.juro.2012.05.079. Epub 2012 Sep 27.
109. Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, Lotan Y, Sun M, Karakiewicz PI, Abdennabi J, Fajkovic H, Loidl W, Chun FK, Fisch M, **Scherr DS**, Shariat SF. Impact of smoking on outcomes of patients with a history of recurrent

- nonmuscle invasive bladder cancer. *J Urol*. 2012 Dec;188(6):2120-7. Doi: 10.1016/j.juro.2012.08.029. Epub 2012 Oct 18.
110. Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, **Scherr DS**, Zerbib M, Shariat SF. Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy. *Ann Surg Oncol*. 2013 Mar;20(3):1027-34. Doi: 10.1245/s10434-012-2708-5. Epub 2012 Oct 26.
 111. Green DA, Osterberg EC, Xylinas E, Rink M, Karakiewicz PI, **Scherr DS**, Shariat SF. Predictive tools for prostate cancer staging, treatment response and outcomes. *Arch Esp Urol*. 2012 Nov;65(9):787-807.
 112. Xylinas E, Cha EK, Sun M, Rink Nm Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, **Scherr DS**, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. *Br J Cancer*. 2012 Nov 20;107(11):1826-32. Doi: 10.1038/bjc.2012.464.
 113. Avgerinos DV, Nazarian M, **Scherr DS**, Girardi LN. Primary adrenal melanoma with inferior vena caval thrombus. *Ann Thorac Surg*. 2012 Dec;94(6):2108-10. Doi: 10.1016/j.athorasur.2012.04.122.
 114. Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Roupret M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, Gontero P, Chun FK, Fisch M, **Scherr DS**, Shariat SF. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. *World J Urol*. 2013 Oct;31(5):1029-36. Doi: 10.1007/s00345-012-0996-9. Epub 2012 Nov 30.
 115. Najari BB, Rink M, Li PS, Karakiewicz PI, **Scherr DS**, Shabsigh R, Meryn S, Schlegel PN, Shariat SF. Sex disparities in cancer mortality: the risks of being a man in the United States. *J Urol*. 2013 Apr;189(4):1470-4. Doi: 10.1016/j.juro.2012.11.153. Epub 2012 Nov 30.
 116. Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, Babjuk M, Pycha A, Lotan Y, Trinh QD, Chun FK, Lee RK, Karakiewicz PI, Fisch M, Robinson BD, **Scherr DS**, Shariat SF. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol*. 2013 Sep;64(3):456-64. Doi: 10.1016/j.euruuro.2012.11.039. Epub 2012 Nov 27.
 117. Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, Lotan Y, Guillonneau B, Weizer A, Pycha A, **Scherr DS**, Seitz C, Sun M, Trinh QD,

- Karakiewicz PI, Montorsi F, Zerbib M, Gonen M, Shariat SF; UTUC Collaboration. Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. *J Urol.* 2013 Feb;189(2):468-73. Doi: 10.1016/j.juro.2012.09.036. Epub 2012 Dec 14.
118. Messer JC, Terrell JD, Herman MP, Ng CK, **Scherr DS**, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JD. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. *Urol Oncol.* 31(6):904-8, 2013
119. Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz PI, Gontero P, Lotan Y, Chun FK, Fisch M, **Scherr DS**, Shariat SF. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. *J Urol.* 2013 Aug;190(2):480-6. Doi: 10.1016/j.juro.2013.01.089. Epub 2013 Jan 31.
120. Johar RS, Hayn MH, Stegemann AP, Ahmed K, Agarwal P, Balbay MD, Hemal A, Kibel AS, Muhletaler F, Nepple K, Pattaras JG, Peabody JO, Palou Redorta J, Rha KH, Richstone L, Saar M, Schanne F, **Scherr DS**, Siemer S, Stokle M, Weizer A, Wiklund P, Wilson T, Woods M, Yuh B, Guru KA. Complications after robot-assisted radical cystectomy: results from the international robotic cystectomy consortium. *Eur Urol.* 2013 Jul;64(1):52-7. doi: 10.1016/j.eururo.2013.01.010. Epub 2013 Jan 16.
121. Da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, **Scherr DS**, Shariat SF. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *J Urol.* 2013 Aug;190(2):487-92. Doi: 10.1016/j.juro.2013.02.003. Epub 2013 Feb 8.
122. Marshall SJ, Hayn MH, Stegemann AP, Agarwal PK, Badani KK, Balbay MD, Dasgupta P, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Palou Redorta J, Rha KH, Richstone L, Schanne F, **Scherr DS**, Siemer S, Stockle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Guru KA. Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). *BJU Int.* 2013 Jun; Int. 2013 Jun; 111(7):1075-80. Doi: 10.1111/j.1464-410X.2012.11583.x. Epub 2013 Feb 26.
123. Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupret M, Pycha A, **Scherr DS**, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Shariat SF; UTUC Collaboration. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone

- radical nephron-ureterectomy. *BJU Int.* 2013 Aug; 112(4):453-61. Doi: 10.1111/j.1464-410X.2012.11649.x. Epub 2013 Mar 6.
124. Rink M, Xylinas E, Trinh QD, Lotan Y, Margulis V, Raman JD, Fisch M, Lee RK, Chun FK, Abdennabi J, Seitz C, Pycha A, Zlotta AR, Karakiewicz PI, Babjuk M, **Scherr DS**, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration. Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. *BJU Int.* 2013 Sep; 112(5):623-37. Doi: 10.1111/bju.12014. Epub 2013 Mar 6.
125. Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, **Scherr DS**, Shariat SF. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Eur J Cancer.* 2013 May; 49(8):1889-97. Doi: 10.1016/j.ejca.2013.02.001. Epub 2013 Mar 4.
126. Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, **Scherr DS**, Gudas LJ, Mongan NP. Estrogen receptor-B expressions and pharmacological targeting in bladder cancer. *Oncol Rep.* 2013 Jul; 30(1):131-8. Doi: 10.3892/or.2013.2416. Epub 2013 Apr 23.
127. Crivelli JJ, Xylinas E, Kluth LA, Da Silva RD, Chrystal J, Novara G, Karakiewicz PI, David SG, **Scherr DS**, Lotan Y, Shariat SF. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. *BJU Int.* 2013 Jul; 112(2):E4-12. Doi: 10.1111/bju.12150.
128. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, **Scherr DS**, Seiler D, Chun FK, Graefen M, Tewari A, Gonen M, Montorsi F, Shariat SF, Briganti A. Pathologic nodal staging scores in patients treated with radical prostatectomy: A postoperative decision tool. *Eur Urol.* 2013 Jul 2. Doi: pii: S0302-2838(13)00656-8. 10.1016/j.eururo.2013.06.041 Epub ahead of print.
129. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, **Scherr DS**, Zerbib M, Vickers AJ, Shariat SF. Accuracy of the EORTC risk tables and the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. *Br J Cancer.* 2013 Sep 17; 109(6):1460-6. Doi: 10.1038/bjc.2013.372. Epub 2013 Aug 27.
130. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Holmang S, Babjuk M, Fajkovic H, Seitz C, Klatter T, Pycha A, Banchmann A, **Scherr DS**, Shariat SF. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. *Eur Urol.* 2014 Jan; 65(1):201-9. Doi: 10.1016/j.eururo.2013.08.034. Epub 2013 Aug 27.

131. Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, Lotan Y, Briganti A, Loidl W, Faison T, Crivelli JJ, **Scherr DS**, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, Shariat SF. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis.* 2013 Dec;16(4):367-71.
132. Kluth LA, Shariat SF, Kratzik C, Tagawa S, Sonpavde G, Rieken M, **Scherr DS**, Pummer K. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. *World J Urol.* 2013 Sep 3.
133. Xylinas E, Kluth LA, Rieken M, Lee RK, Elghouayel M, Ficarra V, Margulis V, Lotan Y, Roupret M, Martinez-Salamanca JI, Matsumoto K, Seitz C, Karakiewicz PI, Zerbib M, **Scherr DS**, Shariat SF; UTUC Collaboration. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. *BJU Int.* 2013 Aug 12. Epub ahead of print.
134. Passoni NM, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson BD, Roupret M, Chun FK, Lotan Y, Roehrborn CG, Crivelli JJ, Karakiewicz PI, **Scherr DS**, Rink M, Graefen M, Schramek P, Briganti A, Montorsi F, Tewari A, Shariat SF. Prognosis of patients with pelvic lymph node metastasis following radical prostatectomy: value of extranodal extension and size of the largest lymph node metastasis. *BJU Int.* 2013 Jul 2. Epub ahead of print.
135. Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Matsumoto K, Ikeda M, Dalpiaz O, Zigeuner R, Aziz A, Fritsche HM, Deliere A, Raman JD, Bensalah K, Al-Matar B, Gakis G, Novara G, Klatte T, Remzi M, Comploj E, Pycha A, Roupret M, Tagawa ST, Chun FK, **Scherr DS**, Vickers A, Shariat SF. Predictors of survival in patients with disease recurrence following radical nephroureterectomy. *BJU Int.* 2013 July 19. Epub ahead of print.
136. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Fajkovic H, Babjuk M, Kautzky-Willer A, Bachmann A, **Scherr DS**, Shariat SF. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. *BJU Int.* 2013 Dec; 112 (8):1105-12.
137. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Pummer K, Lee RK, Faison T, **Scherr DS**, Kautzky-Willer A, Bachmann A, Tewari A, Shariat SF. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. *World J Urol.* 2013 Sept 24. Epub ahead of print.
138. Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie

- BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, **Scherr DS**. A Prospective Pilot Study of 89Zr-J591/PSMA Positron Emission Tomography (PET) in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. *J Urol*. 2013 Oct 14.
139. Al-Daghmin A, Kauffman EC, Shi Y, Badani K, Balbay MD, Canda E, Dasgupta P, Ghavamian R, Grubb R 3rd, Hemal A, Kaouk J, Kibel AS, Maatman T, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi R, Redorta JP, Rha KH, Richstone L, Schanne F, **Scherr DS**, Siemer S, Stöckle M, Wallen EM, Weizer A, Wiklund P, Wilson T, Wilding G, Woods M, Guru KA. Efficacy of Robot-assisted Radical Cystectomy in Advanced Bladder Cancer: Results from the International Radical Cystectomy Consortium (IRCC). *BJU int*. 2013 Nov 13. Epub ahead of print.
140. Xylinas E, Green DA, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, Shariat SF, **Scherr DS**. Robotic-assisted Radical Cystectomy With Extracorporeal Urinary Diversion for Urothelial Carcinoma of the Bladder: Analysis of Complications and Oncologic Outcomes in 175 Patients With a Median Follow-up of 3 Years. *Urology*. 2013 Dec; 82(6):1323-9.
141. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, **Scherr D**, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. *Urol Oncoll*. 2013 Jul; 31(5):566-71.
142. Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Kufer R, Chen YT, Zerbib M, Rubin MA, **Scherr DS**, Shariat SF, Robinson BD. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. *J Urol.*, 191(3):830-41, 2014
143. Kluth LA, Xylinas E, Rieken M, Ghouayel ME, Sun M, Karakiewicz PI, Lotan Y, Chun FK, Boorjian SA, Lee RK, Briganti A, Roupret M, Fisch M, **Scherr DS**, Shariat SF. Impact of perioperative blood transfusion on the outcome of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *BJU Int*. 113(3):393-8, 2014
144. Kluth LA, Xylinas E, Rieken M, Chun FK, Fajkovic H, Becker A, Karakiewicz PI, Passoni N, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, Briganti A, **Scherr DS**, Graefen M, Tewari AK, Shariat SF. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? *Urol Oncol*. 32(1):47, 2014
145. Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Rouprêt M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, **Scherr DS**, Shariat SF; for the UTUC Collaboration. Prediction of

- Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. *Eur Urol.* 65(3):650-8, 2014
146. Rieken M, Xylinas E, Kluth L, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, **Scherr DS**, Briganti A, Kautzky-Willer A, Bachmann A, Shariat SF; UTUC Collaboration. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg oncol.* 40(1):113-20, 2014
 147. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Babjuk M, Bachmann A, **Scherr DS**, Shariat SF. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. *Urol Oncol.* 32(1):49 2014
 148. Ahmed K, Khan SA, Hayn MH, Agarwal PK, Badani KK, Balbay MD, Castle EP, Dasgupta P, Ghavamian R, Guru KA, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Redorta JP, Rha KH, Richstone L, Saar M, **Scherr DS**, Siemer S, Stoeckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Khan MS. Analysis of Intracorporeal Compared with Extracorporeal Urinary Diversion After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. *Eur Urol.* 65(2):340-7 2014
 149. Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, **Scherr D**, Shariat SF, Boorjian SA. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. *Urol Oncol.* 32(1):47 2014
 150. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, **Scherr DS**, Lotan Y, Vickers A, Shariat SF. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol.* 2014 Jan 13, Epub ahead of print.
 151. **Scherr DS.** Commentary on “circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer.” Szarvas T, et al. *J Urol,* 80(3): 13-8, 2012
Urol Oncol, 32(2): 215, 2014.
 152. Rieken M, Schubert T, Xylinas E, Kluth L, Roupret M, Trinh QD, Lee RK, Al Hussein Al Awamih B, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, **Scherr DS**, Briganti A, Bachmann A,

- Shariat SF. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol.* April 13, 2012.(Epub ahead of print)
153. Kluth LA, Abdollah F, Zylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, Lotan Y, **Scherr DS**, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gonen M, Briganti A, Shariat SF. Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. *Br J Cancer*, 111(2): 213-19, 2014.
154. Raza SJ, Field E, Kibel AS, Mottrie A, Weizer AZ, Wagner A, Hemal AK, **Scherr DS**, Schanne F, Gaboardi F, Wu G, Peobody, JO, Koauk J, Redorta JP, Pattaras, JG, Rha KH, Richstone L, Balbay MD, Menon M, Hayn M, Stoeckle M, Wiklund P, Dasgupta P, Pruthi R, Ghavamian R, Khan S, Siemer S, Maatman T, Wilson T, Poulakis V, Wilding G, Guru KA. International Robotic Radical Cystectomy Consortium: A way forward. *Indian J Urol*, 30(3): 314-317, 2014.
155. Al Hussein Al Awamlh B, Wang LC, Nguyen DP, Rieken M, Lee RK, Lee DJ, Flynn T, Chrystal J, Shariat SF, **Scherr DS**. Is continent cutaneous urinary diversion a suitable alternative to orthotopic bladder substitute and ileal conduit after cystectomy? Accepted for Publication, *Br J Urol Int*, 2014.
156. Al Hussein Al Awamlh B, Lee DJ, Green DA, Shariat SF, Nguyen DP, **Scherr DS**. Assessment of the quality-of-life and functional outcomes in patients undergoing cystectomy and urinary diversion for the management of radiation-induced refractory benign disease. Accepted for Publication. *Urology*, 2014.

BOOKS, BOOK CHAPTERS, REVIEWS:

1. **Scherr, DS**, Manyak MJ. Bladder Tumors and Calculi. In Sosa RE, Albala DM, Jenkins AD, Perlmutter, AP, eds. *Textbook of Endourology*. Philadelphia: WB Saunders and Co; 1997
2. **Scherr, DS**, Bosworth J. Steckel J. Complications of brachytherapy in the treatment of localized prostate cancer. In: Smith, Teneja, et al, eds. *Complications of Urologic Surgery*. 3rd ed. 2000.
3. **Scherr DS** and Barocas DA. *Hinman's Atlas of Urologic Surgery*. Principles of non-

- continent urinary diversion. Editor, Joseph A. Smith. In Press. 2007.
4. **Scherr DS** and Wang G. Robotic Assisted Radical Cystectomy. In, Robotic Surgery in Urology., Editor, Li Ming Su, 2013, In Press
 5. **Scherr DS** and Richstone L. Minimally Invasive Surgery in the Lower Urinary Tract, In Campbell's Urology, 2012, In Press.
 6. **Scherr DS** and Lee DJ. Radical Inguinal Orchiectomy. In Glenn's Urology. Editory, Marc Goldstein, 2014, In Press.
 7. Mukherjee S and **Scherr DS**. Multiphoton Microscopy in Urologic Surgery. In, Advances in Image Guided Surgery. Editor, Li Ming Su, Springer Publication, 2014. In Press.

ABSTRACTS/PRESENTATIONS:

1. **Scherr, DS, Simmons R. Russo P. Multifocal renal cell carcinoma: a descriptive analysis [Abstract]. Presented at American Urological Association, Anaheim, CA 2001.**
2. **Scherr, DS, Pavlovich CP, Pitts, WR, Vaughan, ED. Collagen type I Crosslinked N-telopeptide as a urinary marker for osteoporosis in prostate cancer [Abstract]. Presented at American Urological Association, Atlanta, GA. 2000.**
3. **Scherr, DS, Vaughan ED, Wei JT, Chung M, Felsen D, Albright R, Knudsen B. Bcl-2 and P53 expression in clinically localized prostate cancer can predict the response to external beam radiotherapy. [Abstract] Presented at American Urological Association, Dallas, TX. 1999.**
4. **Scherr, DS, Choi B, Su LM, Moomjy M, Schlegel PN, Goldstein M. Pregnancy after testicular sperm extraction at the time of radical orchiectomy for cancer in a solitary testis. [Abstract] Presented at American Urological Association, San Diego, CA, 1998.**
5. **Scherr, DS, Goldstein M: Comparison of bilateral vs unilateral varicocelectomy in men with palpable bilateral varicoceles. Presented at American Urological Association, San Diego, CA. 1998.**
6. **Boorjian S, Ng C, Palese M, Sosa RE, Delpizzo J, Vaughan ED and Scherr DS. Delay in time to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma does not impact postoperative disease status. Presented at 2004 AUA, San Francisco, CA.**
7. **Boorjian S, Ng C, Munver R, Sosa RE, Vaughan ED and Scherr DS. Abnormal urinary cytology predicts increased tumor recurrence in upper tract transitional cell carcinoma treated with endoscopic laser ablation. Presented at 2004 AUA, San Francisco, CA.**

8. Smith E, Albert M, Albert P, You X, Masse D and Scherr DS. **Antigen cross presentation and cross priming in the treatment of superficial bladder cancer: The role of BCG-invoked specific CD8+ T lymphocyte response against bladder tumor antigen.** Presented at 2004 AUA, San Francisco, CA.
9. Richstone L, Shah H, Chen H, Kattan M, Schlegel PN, Vaughan ED, Eastham J, Scardino PT and Scherr DS. **Radical prostatectomy (RRP) in men>70 years old: Effect of age on upgrading, upstaging and accuracy of preoperative nomograms.** Presented at 2004 AUA, San Francisco, CA.
10. Boorjian S, Ng C, Munver R, Sosa RE, Vaughan ED and Scherr DS. **Stage migration of upper tract transitional cell carcinoma: An argument for the continued role of endourologic diagnosis and treatment.** Presented at 2004 AUA, San Francisco, CA.
11. **KAI1 IS A NOVEL BIOMARKER FOR CHROMOPHOBE RENAL CELL CARCINOMA** Eric C Kauffman, Daniel A Barocas, Ximing J Yang, Huixian Liu, **Douglas S Scherr**, Jiangling J Tu. Presented at the 2008 annual meeting of the American Urological Association, Orlando, FL
12. **EXPERIENCE WITH ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL CYSTECTOMY: PERI-OPERATIVE AND SHORT-TERM ONCOLOGIC OUTCOMES** Eric C Kauffman, Casey K Ng, Gerald J Wang, James S Wysock, Daniel A Barocas, Jay D Raman, **Douglas S Scherr**. Presented at the 2008 annual meeting of the American Urological Association, Orlando, FL
13. **IMPACT OF TUMOR LOCATION ON PROGNOSIS FOR UPPER-TRACT UROTHELIAL CARCINOMA: OUTCOMES FROM OVER 1300 PATIENTS** Jay D Raman, Casey K Ng, Vitaly Margulis, **Douglas S Scherr**, Yair Lotan, Karim Bensalah, Eiji Kikuchi, Francesco Montorsi, Richard Zigeuner, Alon Z Weizer, Christian Bolenz, Theresa M Koppie, Nazareno Suardi, Mesut Remzi, Andrea Haitel, Charles C Guo, Christopher G Wood, Marco Roscigno, Shuji Mikami, Cord Langner, J Stuart Wolf, Philipp Strobel, Mario Fernandez, Pierre I Karakiewicz, Shahrokh F Shariat. Presented at the 2008 annual meeting of the American Urological Association, Orlando, FL
14. **DOES HYDRONEPHROSIS ON PREOPERATIVE AXIAL CT IMAGING PREDICT WORSE OUTCOMES FOR PATIENTS UNDERGOING NEPHROURETERECTOMY FOR UPPER-TRACT UROTHELIAL CARCINOMA?** Casey K Ng, Jay D Raman, Shahrokh F Shariat, Steven M Lucas, Aditya Bagrodia, Yair Lotan, **Douglas S Scherr**. Presented at the 2008 annual meeting of the American Urological Association, Orlando, FL

15. **COST COMPARISON OF OPEN VERSUS ROBOTIC CYSTECTOMY** Casey K Ng, Richard K Lee, Anna Borkina, **Douglas S Scherr**. Presented at the 2008 annual meeting of the American Urological Association, Orlando, FL
16. **ROBOTIC VERSUS OPEN RADICAL CYSTECTOMY: PROSPECTIVE COMPARISON OF PERIOPERATIVE OUTCOMES AND PATHOLOGIC MEASURES OF EARLY ONCOLOGIC EFFICACY** Gerald J Wang, Casey K Ng, Daniel A Barocas, Jay D Raman, Philip S Li, **Douglas S Scherr**. Presented at the 2008 annual meeting of the American Urological Association, Orlando, FL
17. **MULTIFOCAL RENAL CELL CARCINOMA: INCIDENCE, RISK FACTORS, AND SURVIVAL** Lee Richstone, **Douglas S Scherr**, Mark Synder, Max Sorbellini, Michael W Kattan, Paul Russo. Presented at the 2003 annual meeting of the American Urological Association, Chicago, IL
18. **OPEN VERSUS ROBOTIC CYSTECTOMY: RE-EXAMINING THE COST COMPARISON** Richard Lee, Casey K Ng, Ming-Ming Lee, **Douglas S Scherr**. Presented at the 2009 annual meeting of the American Urological Association, Chicago, IL
19. **A COMPARISON OF POSTOPERATIVE COMPLICATIONS IN OPEN VERSUS ROBOTIC CYSTECTOMY** Casey K Ng, Eric C Kauffman, Ming-Ming Lee, Brandon J Otto, Alyse Portnoff, Richard K Lee, Michael J Schwartz, **Douglas S Scherr**. Presented at the 2009 annual meeting of the American Urological Association, Chicago, IL
20. **PROSPECTIVE COMPARISON OF PERIOPERATIVE AND PATHOLOGIC OUTCOMES BETWEEN ROBOTIC AND OPEN RADICAL CYSTECTOMY** Gerald J Wang, Casey K Ng, Eric C Kauffman, Ming-Ming Lee, Brandon J Otto, Philip S Li, **Douglas S Scherr**. Presented at the 2009 annual meeting of the American Urological Association, Chicago, IL
21. **COMPARISON OF COMPLICATIONS OF LAPAROSCOPIC VERSUS OPEN PARTIAL NEPHRECTOMY USING THE MODIFIED CLAVIEN GRADING SYSTEM** Ranjith Ramasamy, Casey K. Ng, Jennifer Reifsnyder, James DiPietro, Benjamin Shin, Joseph J. Del Pizzo, **Douglas Scherr**. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
22. **EXPRESSION OF BACILLUS CALMETTE GUERIN RECEPTORS, TLR2 AND TLR4, IN BLADDER CANCER CELLS AND CORRELATION WITH CLINICAL RESPONSE** Eric Kauffman, Timothy D'Alfonso, Brian Robinson, Ming Ming Lee, Huixian Liu, **Douglas S. Scherr**. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA

23. **URETEROILEAL ANASTOMOSIS WITH INTRALUMINAL VISUALIZATION: TECHNIQUE AND OUTCOMES** James Wysock, Gerald Wang, Christopher Barbieri, Casey Ng, Ming-Ming Lee, Michael Schwartz, Stephen Boorjian, **Douglas Scherr**. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
24. **PROSTATE BIOPSY AFTER TREATMENT WITH 5-ALPHA REDUCTASE INHIBITORS MARKEDLY ENHANCES PROSTATE CANCER DETECTION** Steven Kaplan, Richard Lee, Doreen E. Chung, **Douglas Scherr**, Alexis Te, E. Darracott Vaughan. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
25. **MULTI-INSTITUTIONAL VALIDATION OF THE PREDICTIVE VALUE OF PREOPERATIVE HYDRONEPHROSIS FOR ADVANCED STAGE UPPER-TRACT UROTHELIAL CARCINOMA** John Terrell, James Brien, Michael Herman, Casey Ng, **Douglas Scherr**, Benjamin Scoll, Stephen Boorjian, Robert Uzzo, Mark Wille, Scott Eggener, Steven Lucas, Yair Lotan, Shahrokh Shariat, Jay Raman. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
26. **RISK FACTORS FOR THROMBOEMBOLISM AFTER RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS** Eric Kauffman, Casey Ng, Ming Ming Lee, Brandon Otto, Gerald J. Wang, **Douglas S.Scherr**. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
27. **COMBINING TMPRSS2:ERG AND PCA3 IN POST-DRE URINE WITH SERUM PSA TO IDENTIFY PROSTATE BIOPSY CANDIDATES: DEVELOPMENT AND VERIFICATION OF A CLINICALLY PRACTICAL ALGORITHM** Scott Tomlins, Martin Sanda, Simpa Salami, Bharathi Laxman, Meredith Regan, Javed Siddiqui, David Rickman, **Douglas Scherr**, Mark Rubin, John Wei, Arul Chinnaiyan. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
28. **BODY MASS INDEX AND PROSTATE SIZE IMPROVE PERFORMANCE OF A PROSTATE CANCER RISK CALCULATOR AT HIGH LEVELS OF SENSITIVITY FOR PREDICTING PROSTATE CANCER AT INITIAL PROSTATE BIOPSY: RESULTS FROM A PROSPECTIVE, MULTI-CENTER COHORT** Simpa Salami, John Wei, Meredith Regan, **Douglas Scherr**, Javed Siddiqui, Michael Kearney, Robert Eyre, William Dewolf, Mark Rubin, Martin Sanda. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
29. **IDENTIFICATION OF NEPHROMETRIC VARIABLES PREDICTIVE OF RENAL IMPAIRMENT FOLLOWING PARTIAL NEPHRECTOMY** Eugene Cha, Bryan Jeun, Casey Ng, Michael Herman, James Wysock, James DiPietro, Danielle

Shehorn, George Shih, Gerald Wang, **Douglas Scherr**. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA

30. **RELATIONSHIP OF METABOLIC SYNDROMES TO CLEAR CELL HISTOLOGY IN RENAL MASSES** Christopher Barbieri, Casey Ng, Gerald Wang, Joseph Del Pizzo, E. Darracott Vaughan, **Douglas Scherr**. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
31. **EARLY ONCOLOGIC OUTCOMES AND POSTOPERATIVE COMPLICATIONS FOLLOWING ROBOTIC RADICAL CYSTECTOMY** Gerald Wang, Eric Kauffman, Casey Ng, James Wysock, Lee Richstone, Ashutosh Tewari, Philip Li, **Douglas Scherr**. Presented at the 2010 annual meeting of the American Urological Association, San Francisco, CA
32. **PATHOLOGIC AND EARLY ONCOLOGIC OUTCOMES AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM** Matthew H. Hayn, Andrew P. Stegemann, Piyush K. Agarwal, Ketan K. Badani, M. Derya Balbay, Erik P. Castle, Prokar Dasgupta, Nicholas J. Hellenthal, Ashok K. Hemal, David Josephson, A. Karim Kader, Adam S. Kibel, Alex Mottrie, Kenneth Nepple, John G. Pattaras, James O. Peabody, Vassilis Poulakis, Raj S. Pruthi, Joan Palou Redorta, Koon-Ho Rha, Lee Richstone, Matthias Saar, **Douglas S. Scherr**, Stefan Siemer, Michael Stoeckle, Eric M. Wallen, Peter Wiklund, Timothy Wilson, Michael Woods, Bertram Yuh, Khurshid A. Guru. Presented at the 2011 annual meeting of the American Urological Association, Washington, DC
33. **PROGNOSTIC TOOL TO HELP IDENTIFY PT1-3N0 PATIENTS LIKELY TO BENEFIT FROM ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY** Eugene Cha, Thomas Chromecki, Maxine Sun, Robert Svatek, Michael Rink, Mesut Remzi, Yair Lotan, Giacomo Novara, Christian Seitz, Felix Chun, Richard Lee, Karl Pummer, Armin Pycha, Wassim Kassouf, Vincenzo Ficarra, **Douglas Scherr**, Pierre Karakiewicz, Shahrokh Shariat. Presented at the 2011 annual meeting of the American Urological Association, Washington, DC
34. **LAPAROSCOPIC AND OPEN PARTIAL NEPHRECTOMY: COMPARISON OF COMPLICATIONS USING CLAVIEN GRADING SYSTEM** Ranjith Ramasamy, Jennifer Reifsnyder, Casey Ng, Benjamin Shin, James DiPietro, Shahrokh Shariat, Joseph Del Pizzo, **Douglas Scherr**. Presented at the 2011 annual meeting of the American Urological Association, Washington, DC
35. **COMPLICATIONS AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY USING STANDARDIZED REPORTING METHODOLOGY: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM** Matthew H.

Hayn, Andrew P. Stegemann, Nicholas J. Hellenthal, Piyush K. Agarwal, M. Derya Balbay, David Josephson, Adam S. Kibel, Kenneth Nepple, John G. Pattaras, James O. Peabody, Joan Palou Redorta, Koon-Ho Rha, Lee Richstone, Matthias Saar, **Douglas S. Scherr**, Stefan Siemer, Michael Stoeckle, Peter Wiklund, Timothy Wilson, Michael Woods, Bertram Yuh, Khurshid A. Guru. Presented at the 2011 annual meeting of the American Urological Association, Washington, DC

- 36. HIGH RATES OF ADVANCED DISEASE, COMPLICATIONS, AND DECLINE OF RENAL FUNCTION AFTER RADICAL NEPHROURETERECTOMY: FURTHER EVIDENCE TO SUPPORT THE INCREASED USE OF NEOADJUVANT CHEMOTHERAPY?** Jay Raman, Yu-Kuan Lin, Matthew Kaag, Timothy Atkinson, Paul Crispen, Chad Reichard, Scott Eggener, Mark Hockenberry, Thomas Guzzo, Benoit Peyronnet, Karim Bensalah, Jay Simhan, Alexander Kutikov, Eugene Cha, Michael Herman, **Douglas Scherr**, Shahrokh Shariat, Stephen Boorjian. Presented at the 2011 annual meeting of the American Urological Association, Washington, DC
- 37. ROBOTIC RADICAL CYSTECTOMY IS FEASIBLE AND SAFE IN THE TREATMENT OF ADEQUATELY SELECTED OCTOGENARIANS** E. Charles Osterberg, Ranjith Ramasamy, Eleni Greenwood, Justin Dubin, Casey K. Ng, Richard K. Lee, Shahrokh F. Shariat, **Douglas S. Scherr**. Presented at the 2011 annual meeting of the American Urological Association, Washington, DC
- 38. IMMUNOCYTOLOGY IS A STRONG PREDICTOR OF BLADDER CANCER PRESENCE IN PATIENTS WITH ASYMPTOMATIC HEMATURIA** Eugene Cha, Lenuta-Ancuta Tirsar, Shahrokh Shariat, **Douglas Scherr**, Christian Schwentner, Joerg Hennenlotter, Arnulf Stenzl, Christine Mian, Paul Christos, Madhu Mazumdar, Michele Lodde, Armin Pycha, Bernd Schmitz-Drager. Presented at the 2011 annual meeting of the American Urological Association, Washington, DC
- 39. SOLUBLE GP130 PROMOTES PROSTATE CANCER INVASION AND PROGRESSION IN AN IL-6 INDEPENDENT FASHION** Shahrokh Shariat, Thomas Chromecki, Julia Hoefler, Christopher Barbieri, **Douglas Scherr**, Pierre Karakiewicz, Claus Roehrborn, Francesco Montorsi, Zoran Culig, Ilaria Cavarretta Presented at the 2011 annual meeting of the American Urological Association, Washington, DC
- 40. LYMPH NODE YIELD AND PREDICTORS OF EXTENDED LYMPHADENECTOMY AT THE TIME OF ROBOT-ASSISTED RADICAL CYSTECTOMY: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM** Susan J. Marshall, Matthew H. Hayn, Andrew P. Stegemann, Piyush K. Agarwal, Ketan K. Badani, M. Derya Balbay, Erik P. Castle, Prokar Dasgupta, Ashok K. Hemal, David Josephson, A. Karim Kader, Adam S. Kibel,

Alex Mottrie, Kenneth Nepple, John G. Pattaras, James O. Peabody, Vassilis Poulakis, Raj S. Pruthi, Joan Palou Redorta, Koon-Ho Rha, Lee Richstone, Matthias Saar, **Douglas S. Scherr**, Stefan Siemer, Michael Stoeckle, Eric M. Wallen, Peter Wiklund, Timothy Wilson, Michael Woods, Bertram Yuh, Khurshid A. Guru. Presented at the 2011 annual meeting of the American Urological Association, Washington, DC

41. **INTERNATIONAL VALIDATION OF THE PROGNOSTIC VALUE OF SUBCLASSIFICATION FOR AJCC STAGE PT3 UPPER TRACT UROTHELIAL CARCINOMA OF THE RENAL PELVIS** Marco Roscigno, Eugene Cha, Christian Seitz, Giacomo Novara, Thomas F. Chromecki, Hans-Martin Fritsche, Kazumasa Matsumoto, Thomas J. Walton, Joachin Carballido, Luigi Filippo Da Pozzo, Roberto Bertini, Vincenzo Ficarra, Wolfgang Otto, Pierre I. Karakiewicz, Armin Pycha, Harun Fajkovic, Richard Naspro, **Douglas S. Scherr**, Francesco Montorsi, Shahrokh F. Shariat. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
42. **ESTROGEN RECEPTOR BETA EXPRESSION AND PHARMACOLOGIC TARGETING IN TRANSITIONAL CELL CARCINOMA OF THE BLADDER** Eric Kauffman, Brian Robinson, Martin Downes, Katarzyna Marcinkiewicz, Leigh Powell, Ming Ming Lee, **Douglas Scherr**, Lorraine Gudas, Nigel Mongan. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
43. **CLINICAL UTILITY OF NMP22 FOR BLADDER CANCER SURVEILLANCE A MULTI-CENTER CROSS-SECTIONAL STUDY** Eugene K. Cha, Christopher E. Barbieri, Michael Rink, Thomas F. Chromecki, Allison Dunning, Yair Lotan, Harun Fajkovic, **Douglas S. Scherr**, Madhu Mazumdar, Shahrokh F. Shariat. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
44. **LOSS OF SPINK1 EXPRESSION IN UROTHELIAL CARCINOMA OF THE BLADDER IS ASSOCIATED WITH UNFAVORABLE OUTCOME AFTER RADICAL CYSTECTOMY** Michael Rink, Shahrokh F. Shariat, Kyung Park, Bjoern Volkmer, Eugene K. Cha, Brian D. Robinson, Felix K. Chun, Richard Hautmann, **Douglas S. Scherr**, Roland Dahlem, Margit Fisch, Mark A. Rubin, Rainer Kuefer, Juan M. Mosquera. . Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
45. **PILOT STUDY ON THE CORRELATION OF MULTIPHOTON TOMOGRAPHY OF HUMAN TESTIS WITH HISTOLOGY** Bobby B. Najari, Ranjith Ramasamy, Joshua Sterling, Amit Aggarwal, Seema Sheth, Philip S. Li, Manu Jain, Brian D. Robinson, Maria Shevchuck, **Douglas S. Scherr**, Marc Goldstein, Sushmita Mukherjee, Peter N. Schlegel. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA

46. **DISEASE-FREE SURVIVAL AS A SURROGATE FOR 5-YEAR OVERALL SURVIVAL IN UPPER TRACT UROTHELIAL CARCINOMA** Eugene K. Cha, Harun Fajkovic, Michael Rink, Armin Pycha, Allison Dunning, Giacomo Novara, Pierre I. Karakiewicz, Vitaly Margulis, Jay D. Raman, Yair Lotan, Wassim Kassouf, Hans-Martin Fritsche, Karim Bensalah, Alon Weizer, Eiji Kikuchi, Marco Roscigno, Mesut Remzi, Kazumasa Matsumoto, Richard Zigeuner, **Douglas S. Scherr**, Madhu Mazumdar, Guru Sonpavde, Shahrokh F. Shariat. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
47. **COST-EFFECTIVENESS (CE) OF DIFFERENT MANAGEMENT STRATEGIES FOR LOW-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)** David A. Green, Eugene K. Cha, Michael Rink, Philip S. Li, Shahrokh F. Shariat, **Douglas S. Scherr**, Richard K. Lee. . Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
48. **EXTRANODAL EXTENSION IS A POWERFUL PROGNOSTIC FACTOR IN BLADDER CANCER PATIENTS WITH LYMPH NODE METASTASIS** Harun Fajkovic, Eugene Cha, Claudio Jeldres, Brian Robinson, Michael Rink, Thomas Chromecki, Eckart Breinl, Gerhard Donner, Robert Svatek, Derya Tilki, Patrick Bastian, Pierre Karakiewicz, Bjoern Volkmer, Giacomo Novara, Christian Seitz, Guru Sonpavde, Siamak Daneshmand, Yair Lotan, Talia Faison, **Douglas Scherr**, Shahrokh Shariat. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
49. **CLINICAL NODAL STAGING SCORES FOR BLADDER CANCER A NEW PREOPERATIVELY NODAL ASSESSMENT TOOL** Michael Rink, Behfar Ehdaie, Eugene K. Cha, Robert S. Svatek, Thomas Chromecki, Harun Fajkovic, Jens Hansen, Giacomo Novara, Siamak Daneshmand, Yves Fradet, Yair Lotan, Arthur Sagalowsky, Derya Tilki, Patrick Bastian, Wassim Kassouf, Hans-Martin Fritsche, Maximilian Burger, Jonathan I. Izawa, Firas Abdollah, Pierre I. Karakiewicz, Felix K. Chun, Margit Fisch, Guru Sonpavde, **Douglas S. Scherr**, Mithat Gonen, Shahrokh F. Shariat. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
50. **VALIDATION OF VISCERAL METASTASES AND KARNOFSKY PERFORMANCE STATUS SCORE AS PREDICTORS OF ALL CAUSE MORTALITY AND CANCER-SPECIFIC SURVIVAL** Daniel J. Lee, Eugene K. Cha, Hans-Martin Fritsche, Michael Rink, Marko Babjuk, Matthias May, Maximilian Burger, Antonin Brisuda, Viktor Soukup, Jack Baniel, Roy Mano, Armin Pycha, Roman Mayr, Evi Comploj, Robert S. Svatek, Paolo Gontero, **Douglas S. Scherr**, Shahrokh F. Shariat. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA

51. **IS THE NODAL YIELD ASSOCIATED WITH OUTCOMES IN BLADDER CANCER PATIENTS WITHOUT NODAL METASTASIS AT RADICAL CYSTECTOMY?** Michael Rink, Shahrokh F. Shariat, David Green, Eugene K. Cha, Jens Hansen, John P. Fitzgerald, Colin P. Dinney, Giacomo Novara, Yves Fradet, Siamak Daneshmand, Derya Tilki, Patrick Bastian, Wassim Kassouf, Hans-Martin Fritsche, Roland Dahlem, Felix K. Chun, Pierre I. Karakiewicz, Margit Fisch, **Douglas S. Scherr**, Axel Merseburger, Yair Lotan, Robert S. Svatek. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
52. **COMPARISON OF OUTCOMES BETWEEN INTRA-CORPOREAL AND EXTRA-CORPOREAL URINARY DIVERSION AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY – THE IRCC RESULTS** Kamran Ahmed, Matthew H. Hayn, Andrew P. Stegemann, Piyush K. Agarwal, Ketan K. Badani, M. Derya Balbay, Erik P. Castle, Prokar Dasgupta, Reza Ghavamian, Khurshid A. Guru, Ashok K. Hemal, Brent K. Hollenbeck, David Josephson, A. Karim Kader, Adam S. Kibel, Mani Menon, Alex Mottrie, Kenneth Nepple, John G. Pattaras, James O. Peabody, Vassilis Poulakis, Raj S. Pruthi, Joan Palou Redorta, Koon-Ho Rha, Lee Richstone, Matthias Saar, **Douglas S. Scherr**, Stefan Siemer, Michael Stoeckle, Eric M. Wallen, Alon Z. Weizer, Peter Wiklund, Timothy Wilson, Michael Woods, Shamim Kahn. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
53. **HIGH DETECTION RATES OF SIGNIFICANT PROSTATE CANCER OCCUR WITH REPEAT BIOPSIES** Bobby B. Najari, Michael Rink, Jens Hansen, Roman Heuer, Christian Eichelberg, Sascha A. Ahyai, Alexander Haese, Thomas Steuber, Hans Heinzer, Margit Fisch, Luis A. Kluth, Hartwig Huland, Jan Schmitges, Markus Graefen, **Douglas Scherr**, Shahrokh F. Shariat, Felix K. Chun. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
54. **INCORPORATION OF BODY MASS INDEX AND PROSTATE SIZE INTO A NOMOGRAM FOR SELECTING PATIENTS FOR INITIAL PROSTATE BIOPSY: VALIDATION IN THE PROSTATE CANCER PREVENTION TRIAL** Simpa Salami, Meredith Regan, John Wei, Donna Ankerst, Stephen Williams, **Douglas Scherr**, Gerardina Bueti, Javed Siddiqui, William DeWolf, Michael Kearney, Paul Church, Robert Eyre, Mark Rubin, Ian Thompson, Martin Sanda. . Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
55. **RELATIONSHIP OF METABOLIC SYNDROMES TO CLEAR CELL HISTOLOGY IN RENAL MASSES** Christopher Barbieri, Casey Ng, Sagit Goldenberg, James DiPietro, Jennifer Reifsnyder, Benjamin Shin, Kymora Scotland, Gerald Wang, Joseph Del Pizzo, E. Darracott Vaughan, **Douglas Scherr**. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA

56. **ONCOFETAL PROTEIN IMP3 A POTENTIAL BIOMARKER FOR INVASIVE BLADDER CANCER** Eugene K. Cha, Bjoern Volkmer, Francesca Khani, Michael Rink, David A. Green, Yao-Tseng Chen, Juan-Miguel Mosquera, Mark A. Rubin, **Douglas S. Scherr**, Richard Hautmann, Rainer Kuefer, Shahrokh F. Shariat, Brian D. Robinson. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
57. **IS ROBOT-ASSISTED RADICAL CYSTECTOMY EFFECTIVE FOR T3 BLADDER CANCER? RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM** Matthew H. Hayn, Ahmed El-Nahas, Andrew P. Stegemann, Piyush K. Agarwal, Ketan K. Badani, M. Derya Balbay, Erik P. Castle, Prokar Dasgupta, Reza Ghavamian, Ashok K. Hemal, Brent K. Hollenbeck, David Josephson, A. Karim Kader, Shamim Kahn, Adam S. Kibel, Mani Menon, Alex Mottrie, Kenneth Nepple, John G. Pattaras, James O. Peabody, Vassilis Poulakis, Raj S. Pruthi, Joan Palou Redorta, Koon-Ho Rha, Lee Richstone, Matthias Saar, **Douglas S. Scherr**, Stefan Siemer, Michael Stoeckle, Eric M. Wallen, Alon Z. Weizer, Peter Wiklund, Timothy Wilson, Michael Woods, Khurshid A. Guru. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
58. **DEGREE OF VASCULAR SCLEROSIS IN BENIGN PARENCHYMA PREDICTS DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER NEPHRECTOMY** Eugene K. Cha, Steven P. Salvatore, Nathan Osbun, James S. Rosoff, Joshua Halpern, **Douglas S. Scherr**, Shahrokh F. Shariat, Surya V. Seshan. Presented at the 2012 annual meeting of the American Urological Association, Atlanta, GA
59. **DOES CIGARETTE SMOKING AND SMOKING CESSATION INFLUENCE OUTCOMES IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY?** Michael Rink, Evangelos Xylinas, Helena Furberg, Luis A. Kluth, Emily C. Zabor, Behfar Ehdaie, Yair Lotan, Richard K. Lee, Felix K. Chun, Armin Pycha, Pierre I. Karakiewicz, Giacomo Novara, Marek Babjuk, Brian Robinson, **Douglas S. Scherr**, Margit Fisch, Shahrokh F. Shariat. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
60. **OPTICAL COHERENCE TOMOGRAPHY AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY FOR INTRAVESICAL REAL-TIME IMAGING AND STAGING OF BLADDER CANCER** Philip J. Cheng, Guilherme Godoy, Edward J. Sanchez, Alvin C. Goh, Joel W. Slaton, **Douglas S. Scherr**, Seth P. Lerner. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
61. **HUMAN MISMATCH REPAIR PROTEIN EXPRESSION IN BLADDER CANCER** Francesca Khani, Evangelos Xylinas, Bjoern Volkmer, Luis Kluth, **Douglas Scherr**, Mark Rubin, Juan Miguel Mosquera, Richard Hautmann, Rainer Kuefer,

Shahrokh Shariat, Brian Robinson. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA

62. **A PHASE 1 PILOT STUDY OF 99MTC-MIP-1404 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)/CT IMAGING IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY** David Green, Charles Osterberg, Joseph R. Osborne, Anastasia Nikolopoulou, Shankar Vallabhajosula, Stanley J. Goldsmith, Brian D. Robinson, Sagit Goldenberg, John Babich, **Douglas S. Scherr** . Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
63. **FEMALE GENDER IS ASSOCIATED WITH HIGHER RISK OF DISEASE RECURRENCE IN PATIENTS WITH PRIMARY T1 HIGH GRADE UROTHELIAL CARCINOMA OF THE BLADDER** Luis A Kluth, Harun Fajkovic, Evangelos Xylinas, Joseph J Crivelli, Niccolo Passoni, Morgan Rouprêt, Andreas Becker, Evi Comploj, Armin Pycha, Sten Holmang, Amit Gupta, Pierre I Karakiewicz, Yair Lotan, Paolo Gontero, Felix KH Chun, **Douglas S Scherr**, Shahrokh F Shariat. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
64. **VASCULAR SCLEROSIS IN NEPHRECTOMY SPECIMENS IS ASSOCIATED WITH FUTURE DEVELOPMENT OF CHRONIC KIDNEY DISEAS** Eugene Cha, Sasha Druskin, Steven Salvatore, Joshua Halpern, **Douglas Scherr**, Surya Seshan, Shahrokh Shariat. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
65. **PROGNOSTIC VALUE OF BAJORIN CRITERIA FOR CANCER-SPECIFIC SURVIVAL IN PATIENTS WHO HAVE DISEASE RECURRENCE AFTER RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER** Luis A Kluth, Evangelos Xylinas, Michael Rink, Matt Kent, Dan Sjoberg, Marek Babjuk, Antonin Brisuda, Atiqullah Aziz, Hans-Martin Fritsche, Evi Comploj, Armin Pycha, Debasish Sundi, Trinity Bivalacqua, Giacomo Novara, Jack Baniel, Roy Mano, Paolo Gontero, Robert S Svatek, Lukas Lusuardi, Anirban Mitra, Sia Daneshmand, Matthew D. Galsky, Yair Lotan, **Douglas S Scherr**, Shahrokh F Shariat. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
66. **A PILOT STUDY OF ZR89-J591 POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY** David Green, Shoab B. Fareedy, Joseph R. Osborne, Brian D. Robinson, Sagit Goldenberg, Ashutosh Tewari, Michael Herman, Neil Bander,

Douglas S. Scherr. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA

67. **COMPARATIVE ONCOLOGIC EFFECTIVENESS BETWEEN ROBOT-ASSISTED AND OPEN RADICAL CYSTECTOMY** Khurshid Guru, Adam Kibel, Ahmed Aboumohamed, Alex Mottrie, Alon Weizer, Ashok Hemal, Derya Tilki, **Douglas Scherr**, Evangelos Xylinas, Fajkovic Harun, Francis Schanne, Giacomo Novara, Gregory Wilding, H Martin Fritsche, James Peabody, Joan Redorta, John Pattaras, Ketan Badani, Koon Rha, Lee Richstone, Luis Kluth, Mani Menon, Maxine Sun, Mevlana Balbay, Michael Stoekle, Michael Woods, Peter Wiklund, Pierre Karakiewicz, Piyush Agarwal, Prokar Dasgupta, Raj Pruthi, Reza Ghavamian, Sia Daneshmand, Shamim Khan, Stefan Siemer, Timothy Wilson, Wassim Kassouf, Yair Lotan, Yi Shi, Shahrokh Shariat. . Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
68. **DOES INCREASING THE NODAL YIELD IMPROVE OUTCOMES IN PATIENTS WITHOUT NODAL METASTASIS AT RADICAL PROSTATECTOMY?** Luis A Kluth, Evangelos Xylinas, Felix KH Chun, Harun Fajkovic, Pierre I Karakiewicz, Niccolo Passoni, Marianne Schmid, Mike Herman, Yair Lotan, Christian Seitz, Paul Schramek, Mesut Remzi, Wolfgang Loidl, Bertrand Guillonneau, Alberto Briganti, **Douglas S Scherr**, Markus Graefen, Ashutosh Tewari, Shahrokh F Shariat. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
69. **IMPACT OF STATIN USE ON ONCOLOGICAL OUTCOMES OF PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER TREATED WITH RADICAL CYSTECTOMY** Rodrigo Donalisio-da-Silva, Evangelos Xylinas, Luis Kluth, Joseph Crivelli, Daher Chade, Giuliano Guglielmetti, Yair Lotan, Pierre karakiewicz, Maxine Sun, Armin Pycha, Francesco Montorsi, Marc Zerbib, **Douglas Scherr**, Shahrokh Shariat. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
70. **PREDICTION OF INTRAVESICAL RECURRENCE AFTER RADICAL NEPHROURETERECTOMY: DEVELOPMENT OF A CLINICAL DECISION-MAKING TOOL** Evangelos Xylinas, Quoc-Dien Trinh, Luis Kluth, David Green, **Douglas Scherr**, Giacomo Novara, Yair Lotan, Pierre Karakiewicz, Francesco Montorsi, Marc Zerbib, Armin Pycha, Evi Comploj, Morgan Roupret, Jay Raman, Alon Weizer, Christian Seitz, Vitaly Margulis, Shahrokh Shariat. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA
71. **ACCURACY OF THE EORTC RISK TABLES AND OF THE CUETO SCORING MODEL TO PREDICT OUTCOMES IN NON MUSCLE-INVASIVE**

UROTHELIAL CARCINOMA OF THE BLADDER Evangelos xylinas, Matthew Kent, Dan Sjoberg, Luis Kluth, Armin Pycha, Evi Comploj, Yair Lotan, Robert Svatek, Quoc-Dien Trinh, Pierre Karakiewicz, **Douglas Scherr**, Marc Zerbib, Shahrokh Shariat. Presented at the 2013 annual meeting of the American Urological Association, San Diego, CA